Meaningful Use (MU) Frequently Asked Questions

Please note that the information in this document only applies to cancer case reporting with the Tennessee Cancer Registry (TCR). The information below does not pertain to the Immunization Registry, Electronic Laboratory Reporting, Syndromic Surveillance, or any other program areas within the Tennessee Department of Health (TDH).

Who is required to report cancer information to the TCR?
All hospitals, laboratories, facilities and health care practitioners shall report data concerning Tennessee patients who are diagnosed and/or treated for cancer in accordance with Tennessee Code Annotated (T.C.A.) § 68-1-1001.

What is reportable in Tennessee (TN)?
All histologies in the International Classification of Diseases for Oncology, Third Edition (ICD-0-3) with a behavior of /2 or /3 are reportable except:
- Prostatic intraepithelial neoplasia (PIN III) of the prostate (C61.9)
- Carcinoma in situ of the cervix (/2) or cervical intraepithelial neoplasia (CIN III) of the cervix
- Malignant primary skin cancers (C44.0—C44.9) with any of the following histology codes are not required:
  - Malignant neoplasm (8000-8005)
  - Epithelial carcinoma (8010-8046)
  - Papillary and squamous cell carcinoma (8050-8084)
  - Basal cell carcinoma (8090-8110)

Can I submit cancer case information even if I don’t directly treat cancer?
No, if a professional does not diagnose or directly treat cancer then the professional may not satisfy the cancer reporting menu option.

Do I need to have certified EHR software to submit cancer case information?
Yes, before registering, ensure that your EHR software can submit cancer cases and meets 100% of the required certification criteria, CQM domains, and either inpatient or ambulatory CQMs, so you can obtain a CMS EHR Certification ID.

Does Physician Reporting under Meaningful Use replace facility reporting?
No. Physician Reporting under Meaningful Use does not replace hospital and laboratory reporting. It is important to note that hospitals and laboratories cannot demonstrate cancer reporting under Meaningful Use.

Can I claim an exclusion from cancer reporting if I neither diagnose nor treat cancer?
Yes, you may claim this exclusion if you are a professional but do not diagnose or treat cancer.
What HL7 version can TDH currently receive for cancer case reporting? Where can I find Clinical Document Architecture (CDA) specifications for cancer reporting?

TCR is currently able to receive HL7 CDA, Release 2.0 for cancer case reporting following the respective standards and implementation guides. You can find the CDA specifications for cancer case reporting through the Centers for Disease Control and Prevention’s Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries HL7 CDA.

How does MU Stage 2 registration apply to individual physicians not a part of a group practice?

If you are an individual physician who is not coordinating MU Stage 2 reporting with a larger group practice, you will need to register through the Tennessee Department of Health MU website and indicate that you are the primary contact for whom all MU Stage 2 cancer registry communications should be directed. You will not be required to enter a Group National Provider Identifier (NPI) number, but you will be required to enter your Provider NPI number as assigned from the National Plan and Provider Enumeration System.

How does MU Stage 2 registration apply to group practices?

For physicians who belong to a single group practice, under which all MU Stage 2 activities are coordinated, it is recommended that a single person from the practice serve as the primary MU Stage 2 administrator and contact representative. This individual will register all Eligible Professionals (EP) under the practice name and will provide a single group NPI for the practice and a Provider NPI number for each EP.

What can EPs expect after Trading Partner Registration (TPR) is complete?

The TCR will contact registered EPs to begin the onboarding process, which will include establishing a transport method with the TCR to send data for testing and correcting data that fails TCR validity protocols through collaboration with your vendor. The onboarding process may require several test cycles before the data can be validated. The onboarding process will end when the data, that have passed the validation process, are submitted on an ongoing basis during the Provider’s EHR reporting period.

What kind of documentation will TDH provide to me so that I can use that documentation to attest to Meaningful Use?

TDH will provide official electronic letters documenting completed steps and phases throughout the TCR on-boarding process. These letters can be used as documentation for your records.

For more information, please contact the Tennessee Cancer Registry (TCR) within the Tennessee Department of Health (TDH) Office of Cancer Surveillance (OCS) at TNCancer.Registry@tn.gov and please include ‘Meaningful Use Cancer Case Reporting’ in the subject line.